Background & aims: HCV Council 2014, like its predecessor HCV Council 2011, assembled leading clinicians and researchers in the field of hepatitis C to critically evaluate current data regarding best practices for managing patients with chronic hepatitis C virus (HCV).
Methods: Clinical practice statements were developed that reflect the areas of potential controversy with high clinical impact. Faculty members were responsible for reviewing the literature to support or reject these statements. After a review and comprehensive discussion of the data, the HCV Council faculty voted on the nature of the evidence and the level of support for each statement.
Results: The results of the detailed analysis with expert opinion are summarized in this article.
Conclusion: Numerous questions regarding optimal management of certain populations and clinical scenarios remain unanswered. The discussion in the article provides a summary of evidenced-based expert opinion that may help guide clinicians as additional information is developed.
Keywords: direct-acting antiviral; genotype 1a and 1b; genotype 2; genotype 3; hepatitis C virus.
© 2015 The Authors. Liver International Published by John Wiley & Sons Ltd.